Sustained remission of severe resistant autoimmune neutropenia with Campath‐1H

We report the course of a patient with severe autoimmune neutropenia in whom only transient responses occurred with corticosteroids, antilymphocyte globulin and granulocyte‐colony stimulating factor, and who was resistant to treatment with azathioprine, cyclosporin and intravenous immunoglobulin. A...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1997-05, Vol.97 (2), p.306-308
Main Authors: Killick, S. B., Marsh, J. C. W., Hale, G., Waldmann, H., Kelly, S. J., Gordon‐Smith, E. C.
Format: Article
Language:English
Subjects:
Alemtuzumab
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm - therapeutic use
Autoimmune Diseases - therapy
autoimmune neutropenia
Biological and medical sciences
Campath‐1 antibodies
Campath‐1H
Female
Hematologic and hematopoietic diseases
Humans
Infusions, Intravenous
Leukocyte Count
Medical sciences
Middle Aged
Neutropenia - therapy
Other diseases. Hematologic involvement in other diseases
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the course of a patient with severe autoimmune neutropenia in whom only transient responses occurred with corticosteroids, antilymphocyte globulin and granulocyte‐colony stimulating factor, and who was resistant to treatment with azathioprine, cyclosporin and intravenous immunoglobulin. A 10 d course of intravenous Campath‐1H monoclonal resulted in a sustained haematological response. The long‐lasting effect of Campath‐1H may be due to its remarkable ability to induce a profound and prolonged peripheral blood T lymphopenia.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1997.612718.x